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Short summary 25 
Background: Many mutations in the NPHS1 gene were detected among patients with congenital 26 
nephrotic syndrome. Functional analysis of those mutations was done with a stable-expression cell 27 
line. Nevertheless, establishing such a cell line is time-consuming. 28 
Methods and Results: We established an easier method using automatic counting software for 29 
functional analysis with transient-transfection cells rather than a stable-expression cell line. We 30 
demonstrated maltrafficking to the plasma membrane of abnormal nephrin for immunostaining on 31 
transient-expression cells by comparison without Triton X (detecting proteins on the cell 32 
membrane only) and with Triton X (detecting proteins both on the cell membrane and inside the 33 
cell cytoplasm). We obtained relevant results with data obtained previously using a 34 
stable-expression cell line. Furthermore, we conducted functional analysis of NPHS1 mutations in 35 
Japanese patients with congenital nephrotic syndrome using this simple method, which revealed 36 
that all pathogenic mutations impaired trafficking to the protein plasma membrane. 37 
Conclusions: Functional analysis using transient-expression cells with automatic counting 38 
software was useful to demonstrate maltrafficking to the plasma membrane of a protein. All 39 
pathogenic mutations detected in Japanese patients impaired trafficking to the protein plasma 40 
membrane.  41 
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Introduction 42 
Nephrin, the main component protein of the podocyte slit diaphragm complex, plays a major 43 
role in preventing protein loss into urine (Johnstone and Holzman, 2006). Two well-known 44 
mutations cause Finnish-type congenital nephrotic syndrome (Kestila et al., 1998). The NPHS1 45 
gene encodes nephrin protein. Earlier reports have described more than 100 mutations of this gene 46 
detected worldwide in patients with congenital nephritic syndrome (Lenkkeri et al., 1999; Aya et 47 
al., 2000; Koziell et al., 2002; Gigante et al., 2005; Sako et al., 2005; Heeringa et al., 2008; Aya et 48 
al., 2009; Schoeb et al., 2010). In ordinary clinical situations, a mutation found in a patient is 49 
believed to be causative when a substitution of amino acids causes a large change in the Grantham 50 
score (Grantham R, 1974) and when a substituted amino acid is conserved among various species. 51 
Results of functional analyses support that speculation. 52 
Liu et al. (2001) examined functional analysis with cells that stably express a nephrin mutant. 53 
However, establishing a stable-expressing cell line is time-consuming. This study examined 54 
whether functional analysis using transient-expressing cells i  useful or not. Functional analysis of 55 
NPHS1 gene mutations found in Japanese patients was conducted using this method. 56 
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Materials and methods 69 
 70 
Plasmid and mutagenesis 71 
Plasmids were created with each mutation (Quick Change II XL Site-Directed Mutagenesis Kit; 72 
Agilent Technologies Inc., CO, USA) according to the manufacturer’s protocol with 73 
pcDNA3-NPH1, which expresses human nephrin, as template. The primers used to create each 74 
plasmid are shown in the table. Each plasmid was cycle-sequenced using Big-Dye terminators 75 
(Applied Biosystems, CA, USA). The cycle sequence product was analyzed using an automated 76 
sequencer (ABI Prism 310 Genetic Analyzer; Applied Biosystems). 77 
 78 
Cell culture and DNA transfection 79 
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium high glucose (Life 80 
Technologies Inc., CA, USA) supplemented with 10% fetal bovine serum. PDN8, a stable 81 
HEK293 cell line expressing human podocin, was obtained a  described previously (Nishibori et 82 
al., 2004). PDN8 cells were grown in culture medium as described above by adding 200 µg/ml 83 
Zeocin™ (Invitrogen Corp.). Plasmids expressing wild-type or mutated nephrin were transfected 84 
into HEK293 and PDN8 cells according to the manufacturer’s protocol (with Lipofectamine™ 85 
2000; Invitrogen Corp.). 86 
 87 
Western blotting 88 
HEK293 cells were cultured for 48 h after transient transfection with the plasmid cDNA of 89 
wild-type or mutants. Cells were washed with phosphate-buffered saline (PBS) before addition of 90 
hot sodium dodecyl sulfate (SDS) sample buffer [62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% 91 
glycerol, 0.01% bromophenol blue, 50 mM dithiothreitol, and proteinase inhibitor (Complete Mini 92 
EDTA-free; Roche Diagnostics Corp., Mannheim, Germany)]. The cell lysates were collected 93 
using a rubber scraper and were transferred into Eppendorf tubes. The lysates were sonicated, 94 
boiled, and centrifuged for 10 min before loading. After all samples had been subjected to 95 
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SDS-polyacrylamide gel electrophoresis, the proteins were transferred onto nitrocellulose 96 
membranes, which were blocked with Tris-buffered saline containing 5% bovine serum albumin 97 
and 0.1% Tween-20. They were incubated with N20 anti-nephrin antibody (1:1000; Santa Cruz 98 
Biotechnology Inc., CA, USA) overnight at 4 °C. The primary antibody was detected using 99 
horseradish peroxidase-conjugated anti-goat Donkey IgG (Santa Cruz Biotechnology Inc.) and a 100 
Western blot detection system (ECL plus; GE Healthcare UK Ltd., UK). 101 
Two molecular standards were used for SDS-PAGE (Precision Plus Protein Standards, dual 102 
color prestained, cat. no. 161-0374; Bio-Rad Laboratories Inc., CA, USA and Santa Cruz Marker 103 
Molecular Weight Standard, cat. no. sc-2035; Santa Cruz Biotechnology Inc., CA, USA). 104 
 105 
Immunostaining 106 
HEK293 or PDN8 cells were cultured on glass cover slips and were transiently transfected with 107 
the plasmid cDNA of wild-type NPHS1 or mutants. Because podocin is an anchor protein for 108 
nephrin in the cell membrane, the PDN8 cells were used for experiments comparing nephrin on the 109 
cell membrane and inside cells (Roselli S et al. 2002). The PDN8 cells were then cultured further 110 
for 48 h. The cells were washed with PBS and fixed with 2% paraformaldehyde in PBS for 20 min 111 
at room temperature. They were then incubated with 0.1% Triton X-100 in PBS for 5 min for 112 
permeabilization to stain nephrin inside cells. Triton X-100 was not used for detection of nephrin 113 
on the cell membrane. 114 
The cells were incubated with N20 anti-nephrin antibody after incubation with the blocking 115 
buffer (1% bovine serum albumin in PBS) for 10 min. 116 
After washing with PBS, the cells were incubated with Alexa Fluor 488-conjugated donkey 117 
anti-goat IgG (1:200) for 1 h at room temperature. Hoechst33342 was used as the nuclear stain for 118 
the cells. 119 
 120 
Immunofluorescence microscopy and array scan 121 
All immunostained samples were examined using immunofluorescence microscopy (BZ-9000; 122 
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Keyence Co., Osaka, Japan). Nine fields were recorded with every plasmid. 123 
Then, three independent experiments were performed. The Hoechst33342 positive cells 124 
(showing all cells in that field) and Alexa 488 positive cells (showing cells expressing nephrin) in 125 
the immunofluorescence microscope images were counted using Cellomics BioApplications 126 
(Colocalization Ver.3.0; Thermo Fisher Scientific Inc., MA, USA). 127 
 128 
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Results 150 
 151 
Confirmation of anti-nephrin antibody performance 152 
To confirm the antibody performance, immunofluorescence staining was performed with 153 
anti-nephrin antibodies. The HEK293-cell transiently transfected plasmid expresses wild-type 154 
nephrin, p.Glu246*mutant, or no nephrin. The HEK293 was used for confirmation of antibody 155 
performance (Fig. 1). With N20 antibody, wild nephrin and p.Glu246*mutant were stained. N20 156 
anti-nephrin antibody was used to detect wild-type nephrin and mutants. 157 
 158 
Molecular size of nephrin mutants 159 
Using cell lysates containing not only wild-type nephrin but also missense mutants, bands around 160 
185 kD were detected using Western blot with anti-nephrin antibody, as reported previously for 161 
wild nephrin (data not shown). Truncated mutants p.Asp827* (c.2479C > T in exon18) and 162 
p.Gln839fs*8 (c.2515delC in exon 19) each had molecular weight of around 120 kD. The 163 
truncated mutant p.Glu246* (c.736G > T in exon 7) had molecular weight of around 30 kD. 164 
 165 
Expression pattern of wild nephrin 166 
Wild-type nephrin was expressed along the outline in many cells (Fig. 2). No difference was found 167 
in the ratio of Alexa488 positive cells to Hoechst 33342 cells between those with and without 168 
Triton X-100. 169 
The ratio of cells expressing wild nephrin on the cell surface to cells expressing wild nephrin 170 
in and on a whole cell (i.e. the on–in ratio) was almost 1 (Fig. 3). This result indicates that 171 
wild-type nephrin was trafficking to cell membranes in cells that express nephrin inside once. 172 
 173 
Comparison of stably and transiently expressing cells with the same mutants 174 
Preliminarily, mutants already examined in earlier studies (Liu et al., 2001) using the 175 
stable-expression cell line below were used for certification of this transient-expression method: 176 
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p.Ile171Asn mutant, with defect of trafficking to the cell surface; p.Leu376Val mutant, without 177 
defect of trafficking; p.Arg743Cys mutant, without a problem of trafficking, which shows a mild 178 
clinical course; and p.Arg1140Cys mutant, without defect of trafficking, which has an intracellular 179 
mutation site. 180 
The ratio of the number of cells detected using anti-nephrin antibody without Triton X to 181 
those with Triton X (on–in ratio) was found using Cellomics BioApplications. Three experiments 182 
were performed independently, all showing similar on–in ratios. Herein, we present the average of 183 
three independently obtained experiment results (Fig. 3). 184 
The on–in ratio of p.Leu376Val mutant was 0.84. The on–in ratio of p.Arg743Cys mutant was 185 
0.92. The on–in ratio of p.Arg1140Cys mutant was 1.11. That of p.Ile171Asn mutant was 0.36. 186 
The trend of the on–in ratio of these four mutants in transient transfected cells is compatible with 187 
functional analysis using a stably expressing cell line (Liu et al., 2001). 188 
 189 
Functional analysis of NPHS1 mutations from Japanese patients 190 
The on–in ratio with transient transfection method on each mutant from Japanese patients (Aya et 191 
al., 2000; Aya et al., 2009) is shown in Figure 3. The values are averaged results derived from 192 
those obtained from three independent experiments. First, p.Glu246*, p.Arg827*, and 193 
p.Gln839fs*8 (c.2515delC) are truncated mutants. The on–in ratios of the truncated mutants are 194 
small: around 0.40. The ratios of truncated mutants are nearly equal to the ratio of p.Ile171Asn. 195 
These data indicate that these three truncated mutants have defects of trafficking to the cell 196 
surface. Aside from the on–in ratio, few fluorescence-positive cells with Triton X-100 have 197 
protein detected with anti-nephrin antibody both on and in. 198 
Earlier reports (Aya et al., 2000; Aya et al., 2009) have described that four missense mutants 199 
are causative: p.Cys160Ser, p.Arg379Trp, p.Gly601Arg, and p.Val819Asp. The on–in ratios of 200 
these four missense mutants are also small. In contrast, the on–in ratio of p.Glu447Lys, which is 201 
not so causative, is nearly 1 (0.87). These data show that causative mutants detected in Japanese 202 
patients with congenital nephrotic syndrome have defects of trafficking to cell membranes. 203 
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 204 
Discussion 205 
 206 
Liu et al. (2001) reported that functional analysis of nephrin mutants in cultured cells was 207 
performed with a stable-expressing cell line. However, because establishment of a 208 
stable-expressing cell line is time-consuming, this mode of using a stable cell line is unsuitable for 209 
analysis of each mutant detected in patients. Our method of using software for automatic analysis 210 
of transient-expressing cells is not time-consuming. 211 
Liu et al. (2001) reported the p.Ile171Asn mutant with the difficulty of trafficking to the cell 212 
surface. In the transient transfection experiment reported herein, p.Ile171Asn mutant was shown to 213 
have a low rate of expression on the cell surface, which is compatible with results described in 214 
Liu’s report: p.Leu376Val, p.Arg743Cys, and p.Arg1140Cys mutants show no difficulty of 215 
trafficking to the cell surface (Fig. 2). In this experiment, these mutants have a high rate (higher 216 
than 0.8) of expression on the cell surface (Fig. 3). 217 
Among seven missense mutations detected in Japanese patients, four mutations are inferred to 218 
be pathogenic: p.Cys160Ser, p.Arg379Trp, p.Gly601Arg, and p.Asp819Val. The four mutants 219 
have low rates of expression on the cell surface. Moreover, they have difficulty with trafficking to 220 
the cell surface (Fig. 3). 221 
The p.Glu447Lys mutant, which is not regarded as pathogenic, has a high rate of expression 222 
on the cell surface. It presents no difficulty with trafficking to the cell surface (Fig. 3). 223 
The strength of fluorescence itself is influenced by nephrin production capability, degradation 224 
with mutated protein, affinity of the anti-nephrin antibody to each mutant nephrin, and other 225 
factors. In the case of the three truncated mutants, few fluorescence-positive cells with Triton 226 
X-100 have protein detected with anti-nephrin antibody both on and in the cell. Therefore, it is 227 
difficult to ascertain whether the small number of fluorescence-positive cells without Triton X-100 228 
on cells is attributable to the difficulty of trafficking to the cell surface or to other factors such as 229 
low nephrin production capability. However, calculating the ratio of the quantity of fluorescence 230 
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for the cell surface and for the whole cell can resolve that issue. 231 
The three truncating mutations detected in Japanese patients exhibit problems with trafficking 232 
to the cell surface, although some defects aside from trafficking to the cell surface might 233 
contribute to pathogenesis in these patients. 234 
The on–in ratios of four missense mutants that are regarded as pathogenic and three truncating 235 
mutants from Japanese patients and p.Ile171Asn mutant were 0.4–0.6 (Fig. 3). The on–in ratios of 236 
p.Glu447Lys and three missense mutants without problems of trafficking to the cell surface 237 
described in Liu’s report were higher than 0.8 (Fig. 3). 238 
In conclusion, transient transfection is useful for the functional analysis of nephrin. 239 
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Figure Legends 332 
 333 
Fig. 1 Immunostaining for HEK293 cell transfected. 334 
    HEK293 cells expressing wild-type nephrin and p.Glu246* mutant were immunostained with 335 
N20 antibody, with addition of Triton X-100. (magnification × 200) 336 
 337 
Fig. 2 Immunostaining for PDN8 transfected with each vector. 338 
    Transfected cells were immunostained with Hoechst33342 and N20 anti-nephrin antibody 339 
(left panels) without Triton X-100 and (right panels) with Triton X-100: a) wild nephrin; b) 340 
empty vector; c) p.Ile171Asn mutant, maltrafficking, already demonstrated in Liu’s study; d) 341 
p.Arg743Cys mutant, not maltrafficking, already demonstrated in Liu’s study; e) 342 
p.Cys160Ser mutant, putatively pathogenic mutation; f) p.Glu447Lys mutant, putatively 343 
non-pathogenic mutation; g) p.Asp819Val mutant, putatively pathogenic mutation; h) 344 
p.Glu246*, non-sense mutation; and i) c.2515delC, frameshift mutant. (magnification × 200) 345 
 346 
Fig. 3 On–in ratios of nephrin. 347 
     Ratios of Alexa488 positive cells to Hoechst 33342 cells with and without Triton X-100 348 
(on–in ratio). Mutations showing low ratios were p.Cys160 Ser, p.Glu246*, p.Arg379Trp, 349 
p.Asp819Val, p.Asp827*, and c.2515delC, in addition to p.Ile171Asn. 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
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Table primer sets for mutagenesis 359 
Mutation   Primer 
p.Cys160Ser F 5'-ggtagctgcgtggtcaactctgtgtctgggg-3' 
(c.479G>C) R 5'-ccccagacacagagttgaccacgcagctacc-3' 
p.Ile171Asn F 5'-gccagcacctgacaacaccattctcc-3' 
(c.512T>A) R 5'-ggagaatggtgttgtcaggtgctggc-3' 
p.Glu246* F 5'-ggaccccctgtcatctagtggccaggcctgg-3' 
(c.736G>T) R 5'-ccaggcctggccactagatgacagggggtcc-3' 
p.Leu376Val F 5'-gctacgatggtgggtgggctggcggc-3' 
(c.1126C>G) R 5'-gccgccagcccacccaccatcgtagc-3' 
p.Arg379Trp F 5'-ggtggctgggctggtggcagctgctgccc-3' 
(c.1135C>T) R 5'-gggcagcagctgccaccagcccagccacc-3' 
p.Glu447Lys F 5'-gcccagaaactgtggattaagggtcccccag-3' 
(c.1339G>A) R 5'-ctgggggacccttaatccacagtttctgggc-3' 
p.Gly601Arg F 5'-ggagagccccattcaaacgctccgccgccgcc-3' 
(c.1801G>C) R 5'-ggcggcggcggagcgtttgaatggggctctcc-3' 
p.Arg743Cys F 5'-gctcccaccatctgtgccctccaggacccc-3' 
(c.2227C>T) R 5'-ggggtcctggagggcacagatggtgggagc-3' 
p.Asp819Val F 5'-ccagtgcattgtggtcaatggggtggcgc-3' 
(c.2456A>T) R 5'-gcgccaccccattgaccacaatgcactgg-3' 
p.Arg827* F 5'-ggggtggcgcctccagcatgacggctgctcc-3' 
(c.2779C>T) R 5'-ggagcagccgtcatgctggaggcgccacccc-3' 
p.Gln839fs*8 F 5'-gtcagatttgcccccaggtggagcacccc-3' 
(c.2515delC) R 5'-ggggtgctccacctgggggcaaatctgac-3' 
p.Arg1140Cys F 5'-ggcagagccgtattactgctccctgaggg-3' 
(c.3418C>T) R 5'-ccctcagggagcagtaatacggctctgcc-3' 
 360 
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Figure1　	
Wild	 p.Glu246*	   Vector	  
上段：N端側認識抗体	  
下段：C端側認識抗体	
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